Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

NCT02147873 is registered in ClinicalTrials.gov with TetraLogic Pharmaceuticals as lead sponsor.

NCT NCT02147873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02147873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Lead sponsor
TetraLogic Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2014
Completion date
June 30, 2016
Enrollment
118 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelomonocytic leukemia (cmml), myelodysplastic syndrome (mds)